Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$68.51 USD

68.51
852,850

-0.09 (-0.13%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $68.53 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 248)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.

3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

GYN Surgical Sales to Aid Hologic (HOLX) in Q2 Earnings

Strong performance led by MyoSure and NovaSure is expected to have driven Hologic' s (HOLX) Q2 performance.

BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?

Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the supply chain.

DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

DexCom's (DXCM) first-quarter results likely to reflect rising volumes across all channels.

Neogen (NEOG) New Buyouts Aid Growth Amid Rise in Expenses

Neogen's (NEOG) performance of the Food Safety business is strong, driven by several long-term secular tailwinds.

AmerisourceBergen's (ABC) New JV to Boost Oncology Care

AmerisourceBergen's (ABC) new JV is expected to provide the independent community oncology network with additional resources and expertise to grow the platform and improve patient outcomes.

Here's Why You Should Retain NextGen (NXGN) Stock for Now

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

What's in Store for West Pharmaceutical (WST) in Q1 Earnings?

West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

Robust performance from MyoSure and NovaSure along with increasing contributions from the company's laparoscopic portfolio are expected to have contributed to the Hologic's (HOLX) Q2 reveneus.

IDEXX Laboratories (IDXX) to Post Q1 Earnings: What's in Store?

IDEXX Laboratories' (IDXX) first-quarter 2023 results are expected to reflect an impressive performance in the CAG segment despite inflationary impacts.

Henry Schein (HSIC) Gains As Market Dips: What You Should Know

In the latest trading session, Henry Schein (HSIC) closed at $83.01, marking a +0.07% move from the previous day.

Zimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?

Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.

Masimo's (MASI) New FDA Approval to Improve Patient Monitoring

Masimo's (MASI) receipt of the FDA's clearance for the Rad-G with Temperature is expected to support clinicians in almost any care scenario.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

Henry Schein's (HSIC) medical business is expected to have gained from improved U.S. patient traffic to physician offices, ultimate care sites and ambulatory surgical centers.

What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?

Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.

Baxter (BAX) to Post Q1 Earnings: What's in the Offing?

Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down

Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Catalent (CTLT) Declines on Profit Warnings and CFO Exit

Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies in the first quarter.

What's in Store for Thermo Fisher (TMO) in Q1 Earnings?

Thermo Fisher (TMO) is likely to have generated growth in the first quarter, driven by a favorable business mix and new launches.